Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.

Learn More
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

view all Clinical Trials

Overview

Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.

Clinical Trial Information

Protocol

TIRB# 31322

Phase

2

Condition(s)

Idiopathic Pulmonary Fibrosis (IPF), Pulmonary Fibrosis (Including IPF), Interstitial Lung Disease (ILD)

Investigator

Gerard Criner, MD

Coordinator

Debasree Sana Boral

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.

Full Title

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Determine the Safety and Efficacy of Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Related Clinical Trials

Platform Clinical Study for Conquering Scleroderma (CONQUEST)

TIRB # 31547
  • Conditions: Interstitial Lung Disease (ILD)
  • Investigator: Gerard Criner, MD
  • Coordinator: Peter Gavin, Joseph Lambert
View Details

A Study Evaluating the Safety and Efficacy of AP01 in Participants With Progressive Pulmonary Fibrosis (PPF)

NCT06329401
  • Conditions: Interstitial Lung Disease (ILD), Pulmonary Fibrosis (Including IPF)
  • Investigator: Gerard Criner, MD
  • Coordinator: Ashley Cameron, Elaina Budny
View Details

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

TIRB# 31532
  • Conditions: Idiopathic Pulmonary Fibrosis (IPF), Interstitial Lung Disease (ILD), Pulmonary Fibrosis (Including IPF)
  • Investigator: Gerard Criner, MD
  • Coordinator: Kriti Mittal
View Details